RGX-202 Duchenne Gene Therapy Met Its Phase 3 Goal as New Data Detail Two Resolved Serious Side Effects

Ice Water, Math Quizzes, and Shocks: The 1948 Breastfeeding Experiment That Showed Stress Can Slow Milk FlowIn 1948, researchers stressed a nursing mother with ice water, toe pulling, and math problems with shocks. Each time, her baby got less milk. Thanksgiving 2026 Almanac Outlook Calls for Upper Midwest Snow and Eastern Rain as Travelers Plan AheadThe Old Farmer’s Almanac predicts snow in the Upper Midwest and rain in the East for Thanksgiving 2026. Here is how to plan travel safely and stay healthy. Cervical Cancer Screening Gaps Persist in the South and West as At-Home HPV Testing Expands for WomenA new study shows uneven cervical cancer screening across U.S. regions. Here are current Pap and HPV schedules and at-home testing options. Families with Children of Different Citizenship Status Can Check Each Child’s Eligibility for Medicaid or CHIP SeparatelyA JAMA Network Open study finds that over 1 million U.S. children live in families with mixed citizenship status. Learn how Medicaid and CHIP eligibility is decided for each child. Mental Health Bernalillo County Declares Fentanyl Emergency After 314 Overdose Deaths in 2025 as New Mexico Bucks National DeclineBernalillo County declared a fentanyl emergency after 314 overdose deaths in 2025, as New Mexico deaths rise while national deaths fall. Ketamine During or After C-Sections Was Linked to Lower Early Postpartum Depression Scores Across Six TrialsSix trials linked ketamine during or after C-sections to lower early postpartum depression screening scores. The data are early and short-term. Women with Autoimmune Diseases Were Nearly 50% More Likely Than Men to Report Being Given a Psychiatric MisdiagnosisWomen with autoimmune diseases were nearly 50% more likely than men to report a psychiatric misdiagnosis in a 6,607-person survey. What to know. National Depression Screening Advice Was Linked to More Therapy and Less Antidepressant-Only Use Among Distressed AdultsAfter depression screening became routine advice, distressed adults used more therapy and fewer antidepressants alone. What patients can ask. Innovation Kissing May Date Back as Far as 21.5 Million Years to Ape Ancestors, and Neanderthals Probably Kissed TooAn Ig Nobel-winning Oxford study traces kissing to ape ancestors up to 21.5 million years ago, a reminder of how long oral germs have spread. Thyroid Eye Disease Patients Gain First At-Home Injection Option as FDA Clears Roche’s Enspryng for AdultsThe FDA approved Roche’s Enspryng for thyroid eye disease, the first treatment patients or caregivers can inject at home every four weeks. Merck and Moderna Prepare FDA Filing for Personalized mRNA Melanoma Vaccine Paired with Keytruda After Phase 3 ResultsMerck and Moderna are preparing to seek FDA approval for a personalized mRNA melanoma vaccine used with Keytruda. No filing date has been set. Lenire Tinnitus Device Joins U.S. ENT Guidelines as an Option Doctors May Offer for Bothersome RingingUpdated U.S. ENT tinnitus guidelines say doctors may offer Lenire’s bimodal neuromodulation. Here is what the evidence and cost look like. Healthy Living CMS Quietly Restores Coverage for Some of 760,000 Removed ACA Enrollees but Will Not Say How ManyCMS has reinstated some people cut from ACA plans in its fraud sweep but won’t release a count. What HealthCare.gov enrollees should check now. Parents Urged to Stop Using bblüv Grow High Chairs and Papablic Bedside Sleepers After CPSC Finds Infant HazardsCPSC warns parents to stop using bblüv Grow high chairs and recalled Papablic bedside sleepers over fall, entrapment, and suffocation hazards. Massachusetts Moves to Revoke All 12 RegalCare Nursing Home Licenses After Four Immediate Jeopardy Findings in Three YearsMassachusetts moved to revoke all 12 RegalCare nursing home licenses, citing the owner’s unsuitability. What residents’ families should know now. Community Health Center Patients May Soon Hear More About Nutrition, Sleep and Exercise Under Voluntary HHS PushHHS launched a voluntary pledge urging community health centers to focus on nutrition and prevention. What patients may notice and what may not change. Covid – 19 FDA Proposes Requiring Companies to Report Food Additives That Now Reach Grocery Shelves Without Federal ReviewFDA has released its proposed GRAS rule requiring companies to notify the agency about food additives. Here is what the proposal does and does not do. Federal Regulators Warn Some Hair Dryer Brushes Lack the Part That Stops ElectrocutionCPSC warns hair dryer brushes sold on Walmart.com and TikTok Shop lack immersion protection. The seller has not agreed to a recall or refund. A Recalled Teething Toy Broke the Pattern Parents Were Told to Look ForA newly recalled pull-string teething toy has a different model number and design from earlier recalls, and one choking incident has been reported. Trying to Lower Blood Sugar, Cholesterol or Blood Pressure? Different Workouts Suited Different MarkersA pooled analysis of 53 trials found that different exercise types helped different metabolic markers. Most of the evidence was low certainty. Editorial Illustration via AI Share on Twitter Share on Facebook Share on Pocket New data presented at the Child Neurology Society Annual Meeting in Montreal give families the fullest public look yet at RGX-202, an experimental one-time gene therapy for Duchenne muscular dystrophy. The pivotal Phase 3 portion of the AFFINITY DUCHENNE trial met its main goal: average levels of a key muscle protein exceeded a preset threshold 12 weeks after treatment, and 93% of boys with evaluable muscle samples individually crossed that line, NeurologyLive reported on Oct. 16.

The presentation also described two drug-related serious side effects: inflammation of the heart muscle in an 8-year-old and liver injury without symptoms in a 10-year-old. Both resolved without lasting effects, according to the abstract. The developer, REGENXBIO, first announced topline results in May, so the main finding is not new. The conference data matter because they put the safety details and study design in front of the doctors who counsel families.

For parents of boys with Duchenne, the practical question is not whether the trial succeeded on paper. It is what the result measured, what risks came with it, and how soon a treatment might reach clinics. Each answer still carries real uncertainty.

Duchenne is a rare genetic disease, mainly affecting boys, in which the body cannot make enough dystrophin, a protein that protects muscle. The dystrophin gene is too large to fit inside the viral carriers used for gene therapy. RGX-202 instead delivers instructions for microdystrophin, a shortened version designed to keep the protein’s most important parts.

The study’s main goal was a biomarker, not a measure of walking or strength. Researchers took muscle biopsies at week 12 and checked whether average microdystrophin levels exceeded 10% of normal dystrophin levels. The therapy met that goal with strong statistical significance, and among 30 boys with biopsies, 93% individually crossed the threshold.

The Phase 3 group included 31 boys aged 1 and older who could still walk. Each received a single intravenous infusion. Only nine had reached one year of follow-up, and their muscle-function scores were compared with statistically weighted outside comparison groups rather than a placebo group. Higher protein levels tracked with better scores on the North Star Ambulatory Assessment, a standard test of motor function, according to the company.

MedicalDaily Evidence Check: This was an open-label, single-arm, company-sponsored study, so families and doctors knew who received treatment. The functional findings rest on nine boys and outside comparisons. The results were presented by Jahannaz Dastgir, DO, REGENXBIO’s clinical development lead for the program, at a medical meeting, not in a full peer-reviewed paper. The data suggest the therapy produces the target protein, but they do not yet prove it slows the disease over years.

The most common drug-related side effects were vomiting in 19 boys, fatigue in 11, and nausea in 10. The two serious events deserve closer attention because heart and liver problems are known concerns with this type of gene therapy.

REGENXBIO reported that the boy with myocarditis showed no scarring or change in heart pumping strength on his most recent cardiac MRI. Among the nine boys followed for a year, two liver blood markers stayed within normal limits. Children who receive gene therapy are monitored closely for these problems after infusion. Symptoms such as chest pain, shortness of breath, unusual tiredness, or yellowing of the skin or eyes need prompt evaluation by the care team.

Advocates welcomed the earlier topline numbers. “These topline results are exciting for the Duchenne community,” Pat Furlong, founding president of Parent Project Muscular Dystrophy, said in the company’s May release, Contemporary Pediatrics reported. Enthusiasm from families, however, is not the same as long-term proof of benefit.

RGX-202 is not approved, and no family can buy it today. In its second-quarter financial update, REGENXBIO said it planned to begin submitting its application to the FDA in the third quarter of 2026 under the accelerated approval pathway, supporting a possible approval in the second half of 2027. As of Oct. 20, MedicalDaily could not find a public announcement confirming that the filing had started.

Accelerated approval lets the FDA approve a drug based on a biomarker reasonably likely to predict benefit, with confirmatory evidence required later. The company finished dosing its confirmatory study in June, and the planned application will include safety data from 63 boys across the pivotal and confirmatory studies, according to a company announcement on the confirmatory study. REGENXBIO also plans to start a randomized, placebo-controlled study outside the U.S. in the first half of 2027.

A broader policy step may shape reviews like this one. The FDA will hold a public meeting on Oct. 28 on its new Rare Disease Framework Initiative and is accepting public comments through Dec. 11, according to a Federal Register notice. The agency wrote that roughly 1 in 10 Americans lives with a rare disease. Parents can request to speak at the meeting or submit written comments.

For now, families interested in research can ask their neuromuscular specialist about open gene therapy trials, since eligibility rules such as age and walking ability vary by study. Cost and insurance coverage for RGX-202 remain unknown, and current treatment plans should not change based on conference results.

What is RGX-202? It is an experimental one-time gene therapy that delivers instructions for microdystrophin, a shortened version of the muscle protein boys with Duchenne lack.

What did the Phase 3 trial measure? The main goal was whether average microdystrophin levels in muscle biopsies exceeded 10% of normal at week 12. The trial met that goal, and 93% of evaluable boys individually exceeded the threshold.

Were there safety problems? Two drug-related serious events were reported: myocarditis and liver injury without symptoms, and both resolved. Vomiting, fatigue, and nausea were the most common side effects.

Does this prove the therapy slows Duchenne? No. Functional data come from nine boys compared with outside patients, and longer, controlled studies are still needed.

When could it be approved? REGENXBIO has said it is targeting a possible FDA approval in the second half of 2027 if its application proceeds as planned.

Can my son join a trial? Ask a neuromuscular specialist about open studies. Eligibility rules, such as age and walking ability, vary by trial.